在严重喘中生物疗法的现实世界比较有效性:EU-ADVANTAGE
Giorgio Walter Canonica1, Johann Christian Virchow2, Arnaud Bourdin3
1Personalized Medicine, Asthma and Allergy, Humanitas University and Research Hospital IRCCS, Milan, Italy.
在欧洲患者中,杜皮卢马布在减少严重喘恶化和口服皮质类固醇使用方面,与奥马利祖马布,本拉利祖马布和梅波利祖马布相比,在现实世界中表现出更高的有效性.
科学领域:
- 肺部病理学 肺部病理学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 对于欧洲严重喘 (SA) 治疗中的生物药物,现实世界的比较数据有限.
- 这项研究解决了对SA的批准生物药物之间的比较有效性数据的需求.
研究的目的:
- 在欧洲患有严重喘的患者中,比较dupilumab与omalizumab,benralizumab和mepolizumab的实际有效性.
- 评估治疗开始后严重喘恶化和口服皮质类固醇 (OCS) 处方的减少.
主要方法:
- 欧盟-ADVANTAGE研究分析了来自五个欧洲国家的医生的现实数据.
- 包括医生确认的SA开始使用dupilumab,omalizumab,benralizumab或mepolizumab的患者 (≥12岁).
- 治疗权重的反向概率 (IPTW) 和双倍稳健的回归被用于平衡共变量和估计治疗效应.
主要成果:
- 杜皮卢马布与SA恶化风险明显降低相关:22%与奥马利祖马布相比,35%与本拉利祖马布相比,23%与梅波利祖马布相比.
- 杜皮卢马布也导致了OCS处方的显著减少:25%与奥马利祖马布相比,27%与本拉利祖马布相比,21%与梅波利祖马布相比.
- 总共有2739名患者被分析,基线共变量在IPTW后得到平衡.
结论:
- 与其他生物药物相比,杜皮卢马布在管理严重喘恶化和减少OCS依赖方面可能具有更高的现实世界的有效性.
- 这些发现支持dupilumab作为欧洲严重喘患者在现实环境中的潜在更有效的治疗选择.
更多相关视频
07:28Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
相关概念视频
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
